Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Serosal cavity metastasis of malignant tumor is one of the late complications, which seriously affects the quality of life and survival time of patients. HER-2 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors. The HER-2/PD-L1 dual-targeting CAR-T will be investigated in patients with HER2 positive solid tumor serosal cavity metastases.
Epistemonikos ID: 8a34c068a8e8857b3a9a7f1e6df01b8f01f1fae2
First added on: May 08, 2024